Compare Abeona Therapeutics Inc (ABEO) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Conagra Brands Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Conagra Brands Inc trades at $13.84 (market cap $6.71B). The key difference: Conagra Brands Inc is far larger — about 18× Abeona Therapeutics Inc's market cap, and Conagra Brands Inc pays a 9.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CAG | |
|---|---|---|
Market Cap | $373.32M | $6.71B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $20.65 |
52-Week Low | $4.17 | $12.58 |
Enterprise Value | $228.22M | $13.99B |
Dividend Yield | — | 9.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Conagra Brands (CAG) trades at $14.035, down 2.06% on the day, with mixed technical signals and a neutral overall stance. The stock shows modest valuation metrics with a P/E of 10.06 and P/B of 0.81, but faces profitability challenges with a negative net income margin of -0.39%. Recent earnings have been inconsistent, missing estimates in two of the last three quarters. A high dividend yield of approximately 10% is under scrutiny amid concerns over debt levels and slowing growth under new leadership, with the company set to report Q4 earnings on July 15, 2026.
The outlook for CAG is cautious, with potential upside from defensive positioning and dividend income, but significant risks from earnings volatility, high leverage, and dividend sustainability concerns. Investor sentiment is divided, with analysts predominantly neutral, reflecting uncertainty around the company's ability to navigate operational headwinds and debt management effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
